2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Targeted therapies, personalized medicine, and best management approaches will be the central topics of discussion at the 7th New York Lung Cancer Symposium.
Román Pérez-Soler, MD
Professor of Medicine, Chief, Division of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY
Targeted therapies, personalized medicine, and best management approaches will be the central topics of discussion at the 7th New York Lung Cancer Symposium, which is scheduled for Saturday, November 10, at the Crowne Plaza Times Square in New York City.
“The main focus of the conference is to review the latest developments in the treatment of lung cancer that may be of interest to all those oncologists who deal with lung cancer patients, not only thoracic oncologists but also many oncologists in the community who see a lot of solid tumors including lung cancer,” said Román Pérez-Soler, MD.
Pérez-Soler is serving as a program director for the meeting, along with Mark G. Kris, MD, chief of Thoracic Oncology at Memorial Sloan-Kettering Cancer Center in New York City.
The symposium, which is affiliated with Physicians’ Education Resource (PER), is accredited for AMA PRA Category 1 Credit.™
The program is divided into five broad areas: expanding personalized medicine, applying tyrosine kinase inhibitors of EGFR and ALK, clarifying approaches to stage III non-small cell lung cancer (NSCLC), managing special populations, and summarizing therapies in development.
Emerging therapies that will be discussed include immunogenic antibodies aimed at the programmed death-1 (PD-1), heat shock protein inhibitors, approaches for KRAS mutations in NSCLC, and potential agents targeting ROS and RET translocations.
Faculty members will review data presented at the American Society of Clinical Oncology (ASCO) meeting in June and at the European Society for Medical Oncology (ESMO) meeting in September.
Additionally, case-based discussions and question-and- answer sessions with panelists are scheduled.
“If you are interested in having a one-day overview of the latest things that have happened at ASCO and ESMO, New York City will be the place to be to get a real overview of what’s going on,” said Pérez-Soler.
Román Pérez-Soler, MD, is a program director of the 7th New York Lung Cancer Symposium scheduled for November 10, 2012, in New York City. For more information, visit www.gotoper.com.